Status:
ACTIVE_NOT_RECRUITING
New Analytic Tools for aHUS and C3G Diagnosis
Lead Sponsor:
Mario Negri Institute for Pharmacological Research
Conditions:
Hemolytic-Uremic Syndrome
Membranoproliferative Glomerulonephritis
Eligibility:
All Genders
Phase:
NA
Brief Summary
This protocol is part of a larger project, COMPRare (COMPlement-mediated Rare kidney diseases), which has been financed on behalf of the EJP RD (European Joint Programme on Rare Diseases) program of E...
Detailed Description
Atypical Hemolytic Uremic Syndrome (aHUS) and C3 Glomerulopathies (C3G) are ultra-rare conditions in which an uncontrolled complement activation results in renal inflammation with thrombotic microangi...
Eligibility Criteria
Inclusion
- Aim 1
- Inclusion Criteria:
- Male and female patients (children and adults) with C3G diagnosis
- Biobank written informed consent
- Aim 2 Inclusion criteria
- Male and female patients (children and adults) with aHUS diagnosis in acute phase (before any treatment), or in remission either untreated or undergoing anti-C5 treatment at standard dosing
- Written informed consent Exclusion criteria
- Stx-associated HUS
- TTP (ADAMTS13\<10%)
- Plasma therapy within 2 weeks from blood sampling
Exclusion
Key Trial Info
Start Date :
October 4 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT05985122
Start Date
October 4 2023
End Date
October 1 2026
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"
Ranica, BG, Italy, 24020